BRENTWOOD, Tenn., July 07, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it will release its 2026 second quarter financial results after the market closes on Wednesday, August 5, 2026. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, August 6, 2026.
To participate via telephone and join the call live, please register in advance. Upon registration at https://register-conf.media-server.com/register/BI99959d3b30da46f3a101e52cd0e2654d, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.
Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.
About CoreCivic
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.
Michael Burry just shorted one of the best-performing stocks in the market, and the reasoning behind it is worth understanding whether you own semiconductor stocks or not.
The Scion Asset Management founder disclosed a new short position in Micron Technology (NASDAQ: MU) in a Substack post on July 2, entering at $1,051.87 per share. The stock dropped roughly 5.5% on the news, closing at $975.56. Burry also holds existing short positions in Nvidia, Applied Materials, and the iShares Semiconductor ETF (SOXX), and has said publicly that AI-related chip stocks could see a 30% correction from here.
Burry’s argument centers on one word: cyclicality. “Micron defines cyclical like no other,” he wrote, and he backed it up with numbers that are hard to wave away. The stock has suffered 34 drawdowns of more than 30% over the past 42 years. Its median return on invested capital sits at just 4%. Median return on equity comes in at 7%, which Burry called “frankly terrible.” Free cash flow has gone negative in 48% of quarters historically. And right now, Micron is trading further above its 200-day moving average than at any point since 1984, a stretch that includes the dot-com bubble. Burry dismissed the high-bandwidth memory business fueling the current rally as “just another in a very long series” of Micron products rather than a durable competitive edge.
It’s a compelling case built on four decades of history. The problem is that Micron’s most recent quarter does not look like the start of a downturn. For the period ending May 2026, the company posted $41.5 billion in revenue, up 345.7% year over year, with gross margin expanding to 84.6% from 37.7% a year earlier. On the June 24 earnings call, Chief Business Officer Sumit Sadana said customer demand for memory chips remains “well above our ability to supply” across nearly every product category through 2028. Long-term supply contracts, some running five years with prepayments attached, now account for at least half of the company’s revenue. That is not the profile of a business quietly cracking under the weight of a boom-and-bust cycle. It looks like a company locking in demand years in advance.
So which read is right? The piece of Burry’s argument that deserves the most attention isn’t the historical volatility data, it’s what he pointed to as the actual catalyst. South Korea recently announced mega semiconductor projects worth at least 1.35 trillion won, roughly $880 billion, including new fabrication plants from Samsung and SK Hynix. Burry called this “the beginning of the end.” Samsung, SK Hynix, and Micron together control close to 90% of the global DRAM market. When two of the three dominant players start committing hundreds of billions of dollars to new capacity, the pricing power that has driven this year’s memory rally typically doesn’t last forever. Supply eventually catches up to demand, and when it does in this industry, it tends to overshoot.
That dynamic is becoming more real by the day. SK Hynix debuted its U.S. listing today, raising approximately $28 billion in fresh capital, much of which is aimed squarely at expanding memory production capacity. Meanwhile, insiders at Micron have sold $124.9 million worth of shares over the past three months, a detail that doesn’t prove anything on its own but is worth filing away.
None of this settles the debate, and it shouldn’t. Micron is not a small or micro-cap company, but the memory supply chain it sits atop runs through dozens of smaller public names in testing, packaging, specialty materials, and thermal management, all of which trade on the same underlying cycle. When one of the most recognizable short sellers in the market publicly challenges the sustainability of an AI-driven supercycle in the exact stock that anchors that supply chain, the ripple effects extend well past Micron’s own share price. Investors holding exposure anywhere in the memory ecosystem now have a credible bear case sitting alongside the bull case, and the coming quarters, particularly how HBM pricing holds up against the wave of new South Korean capacity, will likely determine who was right.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Asset Sale. CoreCivic sold two detention facilities— the 2,560-bed California City Detention Facility in California City, California, and the 1,994-bed Otay Mesa Detention Facility in San Diego-to the U.S. Government for gross proceeds of $1.5 billion or approximately $1.1 billion in net proceeds. Significantly, CoreCivic expects to continue to manage both facilities under existing management contracts with ICE.
Value Validation. Cal City sold for $286,172 per bed and Otay Mesa for $370,712 per bed. Even acknowledging a “California premium,” the facilities sold significantly above previous sales of detention facilities on a per-bed basis, confirming our long-standing thesis that the Company’s assets are worth well in excess of what the market is giving the Company credit for.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Microsoft (NASDAQ: MSFT) announced this morning that it is cutting 4,800 roles across the company, roughly 2.1% of its workforce. The bulk of the pain, 3,200 positions, lands in the Xbox division. The stock fell more than 1% on the news. Microsoft is now down about 20% year to date, while Alphabet is up 14% and Amazon is up 5%.
But the layoff count is not the story. The story is what Xbox CEO Asha Sharma actually wrote in her memo to employees.
The Quote That Should Get Every Console Investor’s Attention
“Our business today is not healthy,” Sharma told her team. “We are operating at margins that are 3-10x lower than comparable platform and publishing businesses. We must reset XBOX.” She followed it with an even sharper number. “In a typical year, we lost 64 cents for every dollar we invested.”
That is a public admission from a Big Tech executive that an entire business unit has been burning cash at a structural rate. It is unusually blunt, and it is worth paying attention to.
What Is Actually Happening
The first round of cuts includes 1,600 employees today. Microsoft is moving four studios, Ninja Theory, Undead Labs, Compulsion Games, and Double Fine Productions, to outside management. It is working to sell or spin off a fifth, Arkane Studios in France. Sharma also flagged that some workflows pass through 14 layers of management, which she plans to compress to no more than five and ideally three.
Sharma took over Xbox in February and has already cut the price of Game Pass and reworked branding. This move is her most aggressive yet.
The context matters. Microsoft entered this console generation with a smaller install base and higher costs than Sony and Nintendo. The company then poured money into putting first-party games on rival platforms and expanding Game Pass, and the payoff never materialized. Meanwhile, the entire industry is facing a memory and storage crisis that has forced Microsoft, Sony, and Nintendo to raise console prices. Nintendo shares are down 52% over the past twelve months. Sony is off 17%.
The AI Overhang
Microsoft chief people officer Amy Coleman said none of the eliminated roles will be replaced by AI, but acknowledged the technology is changing how work gets done. That is corporate-speak for a much larger issue investors have been chewing on all year. Microsoft is spending heavily on AI infrastructure while the market is questioning whether AI labs will eventually displace demand for Microsoft 365 and its productivity stack. When your legacy cash cow is under pressure and your legacy loss-maker is being amputated on the same day, the market notices.
Why Small and Micro-Cap Investors Should Care
This is not just a Microsoft story. Console economics have propped up a range of small and micro-cap suppliers, developers, and specialty publishers for decades. A serious restructuring at Xbox has downstream implications for independent studios, middleware providers, gaming peripheral makers, and cloud gaming infrastructure names. The four studios moving to outside management, plus Arkane looking for a home, could create acquisition opportunities or standalone independence stories worth tracking.
There is also a broader read-through for anyone holding legacy technology names. When a business as embedded as Xbox can be publicly declared unhealthy by its own leadership, it forces investors to ask which other legacy businesses are quietly burning capital while management waits for the right moment to act.
The Bottom Line
Microsoft is not in trouble. It is a $3 trillion company that just made a hard call on a division that has been dragging on margins for years. But when a Big Tech leader tells you the console model is losing 64 cents on every dollar, believe her. The consumer technology stack is being repriced in real time, and the small caps that live downstream from it are next in line for the same conversation.
Industry veteran brings more than 25 years of technology and digital leadership to newly created role
TROY, Mich., July 06, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, has appointed Alan Stukalsky as chief product and technology officer, effective July 13. Stukalsky joins the Kelly senior leadership team, reporting to CEO Chris Layden, and will be responsible for overseeing the company’s product strategy, technology capabilities, and digital innovation efforts across its portfolio of specialty businesses.
“The workforce solutions industry is at an inflection point. Companies who successfully embed AI into their operations to better serve clients and candidates are going to pull away from the field,” Layden said. “That work is already underway at Kelly. Alan will scale it, drive operational excellence across the enterprise, and accelerate the pace at which we’re launching products that will help clients build tech-enabled workforces. He’s done it before and we’re excited to see the impact he’ll bring.”
Stukalsky brings more than 25 years of technology leadership and digital transformation experience to the newly created role. Throughout his career, he has led large-scale modernization efforts, enterprise platform transformations, cloud migrations, AI-enabled innovation, and the development of new digital business models. He is widely recognized for aligning technology, product, and business strategy to create industry-leading talent solutions and deliver measurable outcomes for customers, employees, and shareholders.
Most recently, Stukalsky served as chief digital and information officer at LHH, part of the Adecco Group. Prior to LHH, Stukalsky spent more than 16 years at Randstad, holding dual executive roles as chief digital officer and chief information officer for North America.
“This is an exciting time to join Kelly. The company is investing in the technology and products that will define how it competes in an AI-driven market,” Stukalsky said. “I’m passionate about making it easier for clients and candidates to work with us, embedding AI into the fabric of how we operate, and ensuring the people we place are equipped with the tools they need to succeed. I look forward to partnering with the talented Kelly team to build on a strong foundation and accelerate growth.”
Stukalsky is a passionate advocate for inspiring future STEM professionals and active with Junior Achievement, Georgia State University’s CIS program, and STE(A)M Truck. He has served on numerous industry and community boards and has been recognized as Georgia CIO of the Year for Large Enterprises. He holds a Bachelor of Science in Mechanical Engineering from Georgia Tech and a Bachelor of Science in Mathematics from Emory University.
About Kelly® Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion.
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a leading media and consumer products company specializing in influencer-led brands through social commerce and livestream shopping, today announced a licensing agreement with KBL Group for OFF/DUTY by Coco Rocha, the elevated fashion and accessories brand created in collaboration with internationally recognized supermodel, entrepreneur, educator, and fashion icon Coco Rocha.
Under the agreement, KBL Group will serve as the production partner for OFF/DUTY by Coco Rocha’s ready to wear collections, leveraging their expertise in sourcing, product development, manufacturing, and supply chain management to bring the brand’s vision to life. The partnership will support the continued growth of OFF/DUTY by Coco Rocha as the brand expands its fashion offerings across multiple retail distribution channels.
OFF/DUTY by Coco Rocha was created to reflect the realities of modern life, offering elevated wardrobe essentials designed for women constantly on the move. Inspired by the pieces Coco has relied on throughout her two-decade career of fashion weeks, international travel, business meetings, and family life. The brand delivers stylish, versatile, and functional pieces that seamlessly transition from day to night.
“KBL Group brings exceptional expertise in product development and manufacturing, making them an ideal partner for OFF/DUTY by Coco Rocha,” said Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands. “As we continue to build the brand, having a best-in-class partner capable of executing Coco’s vision with the highest standards of quality and craftsmanship is critical. We are excited to work together to create collections that resonate with today’s modern consumer.”
David Guisinger, Chief Executive Officer of KBL Group, added, “We are proud to partner with XCEL Brands and OFF/DUTY by Coco Rocha to bring a modern approach to dressing that is both aspirational and accessible. Coco’s authentic point of view and deep understanding of how women dress today have created a powerful foundation for the brand. By combining XCEL’s innovative approach to brand building with KBL’s expertise in product development, sourcing and execution, we are creating a meaningful lifestyle brand that reflects today’s consumer, confident, versatile and effortlessly sophisticated, while developing growth opportunities across multiple channels of distribution.”
About Xcel Brands
Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods, pet products and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel is an industry leader in developing influencer led brands and owns the Halston and C. Wonder brands, as well as the co-branded influencer led brands Tower Hill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and OFF/DUTY by Coco Rocha brand and holds a long-term license agreement in Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers’ shop. The company’s previously owned and current brands have generated more than $5 billion in retail sales via livestreaming in interactive television and digital channels alone and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches more than 46 million social media followers with broadcast reaching 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.
KBL Group is a globally-focused fashion brand development and sourcing partner that supports retailers and designers at every stage of the product lifecycle. With a legacy that traces back to 1985, KBL has evolved into a strategic extension of its clients’ teams, blending market insight, creative design and international supply chain execution into comprehensive brand solutions. Today, KBL Group operates with an integrated presence in New York and Hong Kong, aligning it’s global expertise to help fashion and lifestyle brands navigate a competitive, rapidly-changing marketplace.
Coco Rocha is an internationally recognized supermodel, entrepreneur, educator, author, mentor, and advocate. Often referred to as the “Queen of Pose,” she has spent more than two decades at the forefront of the fashion industry, appearing on hundreds of magazine covers, walking for the world’s leading luxury brands, and starring in major global advertising campaigns.
Beyond modeling, Rocha has built a successful business career spanning fashion, education, television, and digital media. She is the founder of Coco Rocha Model Camp, where she has mentored thousands of aspiring and professional models from around the world, and currently serves as mentor and host of Project Runway Canada. Known for combining creativity, entrepreneurship, and education, Rocha continues to shape the future of fashion while inspiring audiences through her work as a businesswoman, mentor, and mother.
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC’s path forward
CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled “A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS).” The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging therapeutic approaches with the potential to change the course of the disease.
The live webinar will take place on Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time and will be hosted by Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, who covers the biotechnology sector. The discussion will feature Professor Jeremy Shefner, M.D., Ph.D., Chair of Neurology at Barrow Neurological Institute and Co-Founder of the Northeast ALS Consortium (NEALS), together with Alon Ben-Noon, Chief Executive Officer of NeuroSense.
To join the conversation, register in advance here.
The webinar will explore the most pressing questions in ALS drug development today – from the persistent unmet needs that continue to challenge patients and clinicians, to the clinical trial endpoints that may better capture disease progression. The discussion will also examine how NeuroSense’s PrimeC is positioned – mechanistically and clinically – relative to the current standard of care, what the pivotal Phase 3 PARAGON study will aim to demonstrate on the path toward potential FDA accelerated approval, and PrimeC’s longer-term commercial opportunity within an evolving ALS treatment landscape.
About NeuroSense
NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.
NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
106,000 Square Foot Facility Expansion Reflects Increased Demand for Kratos Jet Drones and Kratos’ Continued Investment in Strengthening the United States Defense Industrial Base Through Scalable, Efficient Manufacturing Capacity Capable of Producing Affordable, Mission-Ready Systems at Quantity and at Speed
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced a major expansion of its Oklahoma City manufacturing campus with the addition of over 100,000 square feet of manufacturing and production space. The expansion supports increasing customer demand for the company’s family of high-performance, affordable jet-powered drone systems, including the Valkyrie collaborative combat aircraft, the Firejet/Mighty Hornet IV and others.
The facility expansion represents Kratos’ continued investment in strengthening the United States defense industrial base through scalable, efficient manufacturing capacity capable of producing affordable, mission-ready systems at quantity and at speed. Today, Kratos produces approximately 165 high-performance jet drones annually, and this expansion will enable the company to further increase production to meet growing demand from the U.S. Department of War and allied customers.
“The future fight demands the ability to rapidly produce affordable, high-performance systems at scale,” said Steve Fendley, President of Kratos Unmanned Systems Division. “This expansion in Oklahoma City reflects our long-term commitment to investing ahead of customer demand and building the industrial capacity needed to support the Department of War’s modernization priorities. As autonomous systems become increasingly central to the future force, manufacturing readiness and producing at scale will be just as important as technology readiness, maybe more.”
The expanded facility will provide additional manufacturing, assembly, integration and test capacity for multiple Kratos tactical jet aircraft programs.
Production will support Valkyrie, the affordable, runway-flexible collaborative combat aircraft selected by the U.S. Marine Corps as the foundation of its Collaborative Combat Aircraft (CCA) program of record. Designed to operate solo, in swarms, or alongside crewed aircraft while providing additional mass, reach and mission capability, Valkyrie represents a new generation of affordable autonomous airpower. The expanded facility will also manufacture the Mighty Hornet IV, which is expected to serve as a key tactical capability supporting Taiwan’s defense requirements, reflecting growing international demand for affordable, high-performance unmanned systems.
The expanded facility will also support increased production capacity for Kratos’ family of high-performance aerial target systems, including the Firejet. Kratos’ Firejet system supports realistic operational test, evaluation and weapons training across the U.S. military and allied nations, with demand for advanced target capabilities continuing to grow, including for the test and training of missile, radar, air defense, C-UAS and directed energy weapon systems, and their crews.
Kratos has consistently invested in manufacturing infrastructure, production technologies, and workforce development to ensure the company can deliver affordable systems at the pace and scale required by evolving national security needs. The Oklahoma City expansion is the latest in a series of investments focused on expanding domestic production capacity and strengthening the resilience of the U.S. defense industrial base.
About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.
Notice Regarding Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.
BRENTWOOD, Tenn., July 06, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (CoreCivic or the Company) announced today that on July 2nd, 2026, it completed the sale of its 2,560-bed California City Detention Facility in California City, California (the California City Facility) and its 1,994-bed Otay Mesa Detention Center in San Diego, California (the Otay Mesa Facility) to the United States of America and its assigns, by and through the Department of Homeland Security for an aggregate gross sales price of $1.5 billion, including $732.6 million for the California City Facility and $739.2 million for the Otay Mesa Facility. These two purpose-built facilities were specifically designed to care for individuals in a secure environment. After federal and state income taxes of approximately $0.4 billion and transaction expenses, the Company anticipates its net proceeds from the asset sales to be approximately $1.1 billion.
The Company expects to use a portion of the net proceeds from the asset sales to
Repay all or a portion of the outstanding indebtedness under the Company’s Bank Credit Facility, which currently has an outstanding balance of $270.0 million on the Revolving Credit Facility, $107.8 million on the Initial Term Loan, and $100.0 million on the Incremental Term Loan, and
Repay the remaining outstanding balance of $238.5 million of the Company’s 4.75% senior notes, which are scheduled to mature in October 2027 (the 4.75% Notes).
The Company expects to use the remaining net proceeds for general corporate purposes, which may include additional debt repayments and share repurchases of the Company’s common stock. The credit agreement governing the Company’s Bank Credit Facility (the Credit Agreement) and the indenture (the 2029 Notes Indenture) governing the Company’s outstanding 8.25% senior notes due 2029 (the 8.25% Notes) limit our ability to make certain restricted payments, including share repurchases. However, the Company is permitted to make unlimited restricted payments (i) under the Credit Agreement, to the extent the Company’s consolidated secured leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 1.50 to 1.00 and no default exists thereunder, and (ii) under the 2029 Notes Indenture, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00.
The Company also expects to maintain balance sheet flexibility to pursue growth opportunities. These opportunities include, but are not limited to, potential acquisitions within the Company’s lines of business and those that provide complementary services provided such opportunities enhance the Company’s business, diversify the Company’s cash flows, and/or increase the services the Company offers to its customers, similar to the acquisition of Clinical Solutions Pharmacy completed on April 1, 2026.
The Company currently expects to continue to manage the California City Facility and the Otay Mesa Facility under the existing management contracts with Immigration & Customs Enforcement (ICE) related to each facility, although the terms of the management contracts may be modified to reflect the change in ownership. However, the Company can provide no assurance that it will continue to manage these facilities in the future, or that the terms of the existing management agreements will remain the same. As has always been the case, ICE has the ability to terminate the management contracts for non-appropriation of funds or for convenience. The management contract for the California City Facility expires in August 2027, and the management contract for the Otay Mesa Facility expires in December 2029 and contains a five-year extension option.
In addition to these asset sales, the Company has been in discussions with ICE about the potential acquisition of additional detention facilities from the Company. These discussions are in various stages, and the Company can provide no assurance that any additional sales will occur.
Patrick Swindle, CoreCivic’s President and Chief Executive Officer, commented, “We are pleased with the sales of these two mission-critical facilities for the Company’s government partner, which demonstrates the value of the Company’s underlying real estate portfolio, while reflecting our role as a long-term, flexible solutions provider to government. The sale of these facilities at what we believe is a fair valuation provides the Company with significant balance sheet flexibility and positions us well to grow the Company’s businesses and return value to its shareholders, while remaining a dependable partner for government.”
About CoreCivic
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. CoreCivic has been a flexible and dependable partner for government for more than 40 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.
Forward-Looking Statements
This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy, legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government as a consequence of presidential executive orders, changes in how the federal government, including ICE, elects to use our detention capacity or otherwise procures alternative detention capacity, and the impact of any changes to immigration reform and sentencing laws (we do not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) our ability to successfully activate idle facilities in a timely manner in order to meet the growth in demand for our facilities and services from the federal government that has occurred as a result of changes in policies and actions of the current presidential administration, and to realize projected returns resulting therefrom; (v) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (vi) fluctuations in our operating results because of, among other things, changes in occupancy levels; competition; contract renegotiations or terminations; inflation and other increases in costs of operations, including a rise in labor costs; fluctuations in interest rates and risks of operations; (vii) government budget uncertainty, the impact of debt ceilings and government shutdowns, including partial shutdowns, and changing budget priorities; (viii) our ability to successfully identify and consummate future development and acquisition opportunities, integrate their operations, and realize projected returns resulting therefrom; (ix) the availability of debt and equity financing on terms that are favorable to us, or at all; and (x) the potential for additional sales and intended use of proceeds from the asset sales described in this press release. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.
We take no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.
This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, including the 4.75% Notes or the 8.25% Notes, nor shall it constitute a notice of redemption under the indenture governing the 4.75% Notes or the 2029 Notes Indenture, nor shall there be any offer, solicitation or sale of the 4.75% Notes, the 8.25% Notes or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
New Multi-Year Railcar Order Extends Backlog Visibility and Supports Second Quarter Commercial Momentum, Reflecting Customer Confidence in FreightCar America’s Commercial, Engineering and Manufacturing Platform
CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a leading North American manufacturer and supplier of freight railcars, railcar parts and components, today announced that it has entered into a new multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. The Company also announced that second quarter orders totaled approximately 3,000 railcars, representing a commercial inflection point as demand for differentiated, agile manufacturing solutions continues to grow.
Highlights
Secured a new multi-year order for 1,900 railcars, with deliveries scheduled through 2028, expanding backlog visibility and reflecting customer confidence in the Company’s execution and manufacturing capabilities.
Second quarter orders totaled approximately 3,000 railcars, valued at approximately $300 million, with orders received across every core market segment, reflecting broad-based demand and product diversity.
Multiple first-time customer orders, together with meaningful repeat customer activity, underscore strength of commercial presence, product offering and manufacturing platform.
“Customers are increasingly choosing FreightCar America because we are delivering what the market needs in conditions where customers need us most. Anchored by our engineering capability, manufacturing agility and focus on quality, we continue to position ourselves to gain share and capture significant order momentum during the quarter,” commented Nick Randall, President and Chief Executive Officer of FreightCar America. “This new multi-year commitment for 1,900 railcars is a testament to that, marking a milestone for the Company and showcasing the confidence our customers put into our ability to execute over a sustained delivery horizon.”
Randall continued, “With approximately 3,000 railcars ordered in the quarter, we are seeing an inflection point in terms of commercial momentum across our differentiated product portfolio. These orders highlight the value customers place on our ability to move quickly, tailor solutions to their needs and support transportation capacity across the North American supply chain. We believe FreightCar America is well positioned as an execution-focused railcar manufacturer in a market where reliability, responsiveness and delivery performance matter more than ever.”
Certain orders referenced in this release are subject to customary documentation and completion of terms.
About FreightCar America
FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.
Forward-Looking Statements
This press release contains statements relating to our expected financial performance, financial condition, and/or future business prospects, events and/or plans that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. These potential risks and uncertainties relate to, among other things, the cyclical nature of our business; adverse economic and market conditions, including inflation; material disruption in the movement of rail traffic for deliveries; fluctuating costs of raw materials, including steel and aluminum; delays in the delivery of raw materials; our ability to maintain relationships with our suppliers of railcar components; our reliance upon a small number of customers that represent a large percentage of our sales; the variable purchase patterns of our customers and the timing of completion, delivery and customer acceptance of orders; the highly competitive nature of our industry; potential unexpected changes in laws, rules, and regulatory requirements, including tariffs and trade barriers; and other competitive factors. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.
NN to manufacture critical components for a leading robotic-assisted surgery platform
CHARLOTTE, N.C., July 06, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) (“NN” or the “Company”), a global diversified industrial company that engineers, co-develops and manufactures precision components and assemblies with six sigma quality, today provided an update on developments in its Medical Products business, one of the Company’s key targeted growth markets. The components of the Medical Products growth program are:
Specialized quality control systems in the plants that make medical products
Global footprint in North America, China, South America, Europe
NN has achieved awards to support major OEMs in Ultrasound, Interventional Cardiology, Sports Medicine & Extremity Solutions, and Robotic-Assisted Surgery. Robotic-Assisted Surgery is a new breakthrough area of success and the focus of this press release. NN has now become qualified and has received initial POs tied to a leading robotic-assisted surgery platform. This momentum complements NN’s legacy medical work in surgical instruments, orthopedic tools/components, electrosurgical products, suture-related products, and precision medical components.
A recent and most difficult step to entering the Robot-Assisted Surgery market was passing a critical full-facility audit at NN’s Kentwood, Michigan plant. Successfully passing this audit was made possible by completing a multi-year investment program and installing a new quality system. With this new medical certification now steady-state, a large and well-known new customer has released its first purchase orders to NN, with immediate delivery and ramp-up requirements. This also provides NN with references and an avenue to quote and win additional programs.
With this new customer, the new medical certification, and new medical products, NN’s medical new business pipeline has increased in size by ~$25 million and is now approximately $75 million overall. This is now a meaningful component of NN’s total corporate new business pipeline of >$750 million which includes all products for all markets.
Robotic-assisted surgery is the fastest-growing method of surgical care, expanding at double-digit annual rates in the United States. The underlying growth of this key market reflects a strong secular growth opportunity for precision component suppliers like NN that possess the critical engineering capability, quality systems, and global manufacturing footprint to serve it. NN is uniquely positioned to participate in medical market growth as a qualified manufacturer. NN is actively investing into the medical market with dedicated staff, tradeshow attendance, additional equipment, and new products.
Harold Bevis, President and Chief Executive Officer of NN, Inc., commented, “This is a milestone event for NN’s medical products growth program and a direct payoff on the investments we have made over the last three years to establish a premier presence in this medical market. We needed to upgrade our quality system to the medical level and we have done it.
“Medical Products is one of our five targeted growth markets and we have been very deliberate about building the capabilities required to compete and win. This includes specialized machines, dedicated floor space, certified quality systems, and a dedicated medical team. Passing this full facility quality audit and securing our first newly associated purchase orders to make precision components for a leading robotic surgery platform is a good step forward for NN.”
Bevis continued, “Our precision stainless steel machining expertise supports these new markets well. We are successfully executing on our stated growth goals in the medical products market, and we intend to both grow with this particular customer, as well as more fully participate in the broader medical market.
“This medical products achievement is consistent with our growth program overall. We are partnering for long-term success with OEM category winners. We are successfully building the Company’s business profile in new markets and with new customers. Safety-critical, engineered components are our core value proposition. We support it with a clever team, material science, six sigma quality, and global manufacturing footprint. The medical products achievements announced today, combined with the strong momentum we are experiencing in data center and defense, continue to demonstrate that our entrepreneurial breakout growth program is working well.”
Bevis concluded, “NN is underway with a multi-year program of growing its business into new areas. It is awesome to have the Medical Products portion of the 5 Pillar growth program achieving breakthrough victories. The 5 pillars of break-out growth continue to be: data center and electric grid, defense and electronics, medical products, high-value vehicle products, and high-value stamped products.
We will combine this Medical Product new win information with our recent new wins in Data Center and adjust 2026 sales, adjusted EBITDA, and New Wins guidance, if needed, during NN’s next business and guidance update in August. We look forward to discussing this big advancement during that time.”
About NN, Inc. NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, South America, Europe, and China. For more information about the company and its products, please visit www.nninc.com.
Forward-Looking Statements This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the future growth of NN’s medical business, including NN’s expectations regarding current and future customers and programs, the size and future outlook of the medical market, including robotics-assisted surgery, NN’s competitive position in the medical market, expected new business wins for 2026, and NN’s 2026 performance and other statements that are not historical facts.
Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project”, “achieve,” “growth,” “enable,” “improve,” or the negative of these terms, and similar words, phrases or expressions that convey uncertainty of future events or outcomes. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, general economic conditions and economic conditions in the industrial sector; competitive influences; risks that current customers will commence or increase captive production; risks of capacity underutilization; quality issues; inflationary pressures and material changes in the costs and availability of raw materials, supply chain shortages and disruptions, the availability of labor and labor distributions along the supply chain; our dependence on certain major customers, some of whom are not parties to long-term agreements (and/or are terminable on short notice); the impact of acquisitions and divestitures, as well as expansion of end markets and product offerings; our ability to hire or retain key personnel; the restrictions contained in our debt agreements; the level of our indebtedness and our ability to financing at favorable rates, if at all, or to refinance existing debt as it matures; our ability to secure, maintain or enforce patents or other appropriate protections for our intellectual property; the impact on climate change on our operations; economic, social and geopolitical instability, military conflict, currency fluctuations, and other risks of doing business outside of the United States; and uncertainty of government policies and actions in respect to global trade and tariffs, including the potential impacts of tariffs on the United States economy, the economy of other countries in which we conduct operations and our industry, cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the U.S. Securities and Exchange Commission. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.
Investor & Media Contact: Joe Caminiti [email protected] 312-445-2870
Ondas Inc. (NASDAQ: ONDS) went from a small-cap autonomous systems name to a serious player in the defense technology conversation this morning. The company announced it has closed on the acquisition of DZYNE Technologies for $875.8 million, a deal that reshapes the company’s revenue base, its product portfolio, and arguably its entire investment thesis.
The transaction was funded through a mix of cash and stock. DZYNE shareholders received $200 million in cash and roughly 85 million Ondas shares valued at approximately $675 million. That leaves the DZYNE group, led by private equity firm Highlander Partners, holding about 13.8% of Ondas’ outstanding shares. More than half of the equity consideration, 45 million shares, is subject to a six-month lock-up. That is a meaningful signal about how the sellers view the combined company.
What Ondas Just Bought
DZYNE is a U.S. defense technology company known for long-endurance autonomous aircraft, counter-drone systems, and what the industry now calls “autonomous effects.” Translated, that means expendable, low-cost unmanned platforms designed to be deployed at scale rather than treated as high-value single assets. The Pentagon has been pushing this “affordable mass” concept aggressively, and DZYNE sits directly in the middle of it.
The DZYNE portfolio brings three distinct franchises to Ondas. ULTRA is a long-endurance ISR aircraft with tens of thousands of operational flight hours already logged. IonStrike is a kinetic counter-drone interceptor purpose-built to defeat Shahed-136 class attack drones, the kind that have become a defining threat in modern conflict. Blitz is a Group 1 UAS with 150 kilometers of range and swarm capabilities. Grasshopper is an autonomous cargo glider that delivers up to 500 pounds into contested environments. Add Dronebuster, one of the most widely fielded handheld counter-drone systems in the world, and Ondas now owns a portfolio that has absorbed more than $500 million in cumulative R&D.
The Financial Case
This is where the story gets interesting for small-cap investors. DZYNE is expected to generate $191 million in revenue for 2026 and more than $300 million in 2027. The company is already EBITDA positive with margins targeted in the mid-teens for 2027 and the mid-20% range by 2028.
Ondas raised its 2026 revenue target to at least $525 million, up meaningfully from the prior target of at least $390 million. That figure includes DZYNE and the Omnisys acquisition that closed in May, but does not yet include Cyberhawk, which is expected to close in the third quarter. The company is guiding to a greater than 80% revenue CAGR from 2025 through 2028.
Ondas Sentinel
To manage the expanding U.S. defense portfolio, Ondas is forming a new operating division called Ondas Sentinel. It will house DZYNE alongside World View, the stratospheric platform business Ondas already owned. Ryan Hartman, currently CEO of World View, will run Ondas Sentinel as CEO. Matt McCue, co-founder and CEO of DZYNE, becomes CTO. The structure gives Ondas an integrated ISR stack that spans stratospheric sensing, long-endurance theater ISR, and tactical-edge autonomous operations, all connected through SkyWeaver, a mission software layer being built on Palantir Foundry and AIP.
The Bottom Line
Small-cap defense has been one of the most active corners of the market this year, and Ondas just planted a flag. The company is now positioned as a serious platform play in autonomous defense, with real revenue, positive EBITDA contribution, and a product suite aligned to the exact priorities the Department of War is funding. Execution risk on integration is real, and the share issuance is meaningful dilution. But the pro forma company Ondas described this morning looks very different from the one investors owned last week.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We Are Initiating Coverage With An Outperform Rating. NanoViricides has a proprietary technology platform that it has used to formulate antivirals with a unique mechanism of action. These drugs, called nanoviricides, have been designed to carry a peptide sequence that the virus recognizes as a binding site on a host cell, effectively acting as decoys that the virus binds to instead of healthy cells. Once bound to the drug, the virus is trapped and neutralized.
NV-387 Addresses Viral Outbreaks and Pandemic Preparedness. The lead product, NV-387, is in development for MPox, Ebola, and smallpox. A Phase 2a trial evaluating NV-387 for treating MPox in the Democratic Republic of Congo (DRC) is expected to begin treatment in mid-2027, followed by a Phase 2a in Ebola. Initial data is expected to be available toward the end of 2027.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
